SCHEMBL6645652

SCHEMBL6645652

Cc1ccc(S(=O)(=O)OC2CN(C(C)(C)C)C2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.52
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 2/20 0.45
CYP2C19 P33261 2/20 0.45
VDR P11473 1/20 0.39
GAA P10253 2/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 3/20 0.37
PKM P14618 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ATM Q13315 1/20 0.37
ACHE P22303 1/20 0.36
LMNA P02545 3/20 0.36
MAPK1 P28482 2/20 0.36
MEN1 O00255 2/20 0.36
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9699107 0.88 CYP2D6 (0.58) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL19126918 0.86 CYP2D6 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19GAA
SCHEMBL18173553 0.86 CYP2D6 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19GAA
SCHEMBL6121238 0.85 CYP2D6 (0.64) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL5746294 0.81 CYP2D6 (0.47) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL28411791 0.79 CYP2D6 (0.55) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL14994849 0.79 CYP2D6 (0.42) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL31017317 0.79 CYP2D6 (0.47) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL30496326 0.79 CYP2D6 (0.47) CYP2D6CYP1A2CYP3A4CYP2C19VDR
SCHEMBL11470495 0.78 CYP2D6 (0.52) CYP2D6CYP1A2CYP3A4CYP2C19VDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6809199-B2 ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES MERCK & CO., INC. 2004-10-26 US disclosed
EP-1345603-A4 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO INC (US) 2004-09-08 EP disclosed
EP-1345603-A1 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS Merck & Co., Inc. (US) 2003-09-24 EP disclosed
WO-2002058695-A9 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO INC (US) 2003-09-12 WO disclosed
US-20030092712-A1 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents MERCK SHARP & DOHME CORP. 2003-05-15 US disclosed
WO-2002058695-A1 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO., INC. (US) 2002-08-01 WO disclosed
US-4183923-A 3-ALKANESULFONYLOXYAZETIDINES SCHERING CORPORATION (US) 1980-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092712-A1 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents MAPK1, MAPK7, MAPKAPK2 CYP2D6 2191/4885CYP1A2 1342/4885CYP3A4 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.